StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Aclaris Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Aclaris Therapeutics's price to book ratio was 4.9× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 0.4× to 6.8×, with a median of 3.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.9×+2.2
2025Dec 31, 20252.7×+1.4
2024Dec 31, 20241.4×+0.9
2023Dec 29, 20230.5×−4.3
2022Dec 30, 20224.8×+0.7
2021Dec 31, 20214.1×−2.7
2020Dec 31, 20206.8×+5.9
2019Dec 31, 20190.9×−0.6
2018Dec 31, 20181.6×−1.5
2017Dec 29, 20173.1×−4.1
2016Dec 30, 20167.2×–

More Aclaris Therapeutics figures

See a number that looks wrong?